Opportunities and Obstacles in the Prevention of Skin and Soft-Tissue Infections Among Military Personnel.

Eugene V Millar, Carey D Schlett, Natasha N Law, Timothy J Whitman, Michael W Ellis, David R Tribble, Jason W Bennett
Author Information
  1. Eugene V Millar: Infectious Disease Clinical Research Program, Preventive Medicine & Biostatistics Department, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD 20814.
  2. Carey D Schlett: Infectious Disease Clinical Research Program, Preventive Medicine & Biostatistics Department, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD 20814.
  3. Natasha N Law: Infectious Disease Clinical Research Program, Preventive Medicine & Biostatistics Department, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD 20814.
  4. Timothy J Whitman: Department of Infectious Diseases, Walter Reed National Military Medical Center, 8901 Wisconsin Avenue, Bethesda, MD 20852.
  5. Michael W Ellis: Department of Medicine, University of Toledo College of Medicine and Life Sciences, 3045 Arlington Avenue #3, Toledo, OH 43614.
  6. David R Tribble: Infectious Disease Clinical Research Program, Preventive Medicine & Biostatistics Department, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD 20814.
  7. Jason W Bennett: Walter Reed Army Institute of Research, 503 Robert Grant Avenue, Silver Spring, MD 20910.

Abstract

INTRODUCTION: Skin and soft-tissue infections (SSTIs) are an important cause of infectious disease morbidity among military populations. Due to the high direct and indirect costs associated with SSTIs, particularly with methicillin-resistant Staphylococcus aureus (MRSA) infections, there remains a critical need for the development and evaluation of SSTI prevention strategies among high-risk military personnel. Herein, we review efforts of the Infectious Disease Clinical Research Program (IDCRP) related to the prevention of SSTIs in the military.
METHODS: The IDCRP of the Uniformed Services University has conducted clinical research protocols on SSTI epidemiology and prevention among military personnel since 2009. Observational studies have examined the epidemiology of Staphylococcus aureus colonization and SSTI in training and deployment settings. Two randomized controlled trials of personal hygiene strategies for SSTI prevention at Marine Corps Base Quantico (Virginia) and Fort Benning (Georgia) were performed. Lastly, two vaccine trials have been conducted by the IDCRP, including a Phase 2 S. aureus vaccine trial (currently ongoing) among military trainees.
RESULTS: Military recruits and deployed personnel experience an intense and prolonged exposure to S. aureus, the major causative agent of SSTI. The burden of S. aureus colonization and SSTI is particularly high in military trainees. Hygiene-based trials for S. aureus decolonization among military trainees were not effective in reducing rates of SSTI. In January 2018, the IDCRP initiated a Phase 2 S. aureus vaccine trial among the US Army Infantry training population at Fort Benning.
CONCLUSIONS: In the military, a disproportionate burden of SSTIs is borne by the recruit population. Strategies relying upon routine application of agents for S. aureus decolonization have not been effective in preventing SSTIs. A novel S. aureus vaccine candidate is being currently evaluated in a military training population and may represent a new opportunity to prevent SSTIs for the military.

Keywords

References

  1. Infect Control Hosp Epidemiol. 2010 Dec;31(12):1207-15 [PMID: 21028984]
  2. MSMR. 2017 Jul;24(7):2-11 [PMID: 28731725]
  3. PLoS One. 2012;7(11):e49900 [PMID: 23152934]
  4. Am J Infect Control. 1993 Aug;21(4):205-9 [PMID: 8239051]
  5. Emerg Infect Dis. 2004 May;10(5):941-4 [PMID: 15200838]
  6. Mil Med. 2016 Jun;181(6):524-9 [PMID: 27244061]
  7. Clin Infect Dis. 2003 Dec 15;37(12):1629-38 [PMID: 14689344]
  8. Infect Immun. 2006 May;74(5):3039-41 [PMID: 16622247]
  9. Clin Infect Dis. 2014 Jun;58(11):1540-8 [PMID: 24633684]
  10. Mil Med. 2012 Nov;177(11):1335-42 [PMID: 23198510]
  11. Am J Infect Control. 2016 Dec 1;44(12):1681-1683 [PMID: 27658767]
  12. Infect Control Hosp Epidemiol. 2006 Feb;27(2):185-7 [PMID: 16465636]
  13. Crit Care Med. 2009 Jun;37(6):1858-65 [PMID: 19384220]
  14. Infect Control Hosp Epidemiol. 2007 Sep;28(9):1036-43 [PMID: 17932823]
  15. PLoS One. 2011;6(7):e22407 [PMID: 21818321]
  16. Clin Microbiol Infect. 2010 May;16(5):425-31 [PMID: 19689469]
  17. Vaccine. 2012 Dec 14;30(52):7594-600 [PMID: 23099329]
  18. Antimicrob Agents Chemother. 2015 Feb;59(2):943-9 [PMID: 25421482]
  19. J Clin Microbiol. 2004 Sep;42(9):4050-3 [PMID: 15364988]
  20. J Infect Dis. 2006 Jan 15;193(2):172-9 [PMID: 16362880]
  21. Clin Infect Dis. 2012 Mar;54(6):743-51 [PMID: 22198793]
  22. Clin Microbiol Infect. 2014 May;20 Suppl 5:66-75 [PMID: 24476315]
  23. Ann Intern Med. 1991 Jan 15;114(2):101-6 [PMID: 1898585]
  24. N Engl J Med. 2013 Jun 13;368(24):2255-65 [PMID: 23718152]
  25. Infect Control Hosp Epidemiol. 2012 Aug;33(8):809-16 [PMID: 22759549]
  26. mSphere. 2016 Oct 5;1(5): [PMID: 27747300]
  27. Hum Vaccin Immunother. 2017 Apr 3;13(4):791-801 [PMID: 28010246]
  28. Cochrane Database Syst Rev. 2007 Apr 18;(2):CD004985 [PMID: 17443562]
  29. PLoS One. 2015 May 27;10(5):e0128071 [PMID: 26018036]
  30. Proc Natl Acad Sci U S A. 2014 Dec 23;111(51):E5555-63 [PMID: 25489065]
  31. MSMR. 2013 Jan;20(1):12-5; discussion 15-6 [PMID: 23373867]
  32. Am J Infect Control. 1992 Jun;20(3):138-41 [PMID: 1636934]
  33. PLoS One. 2016 Oct 25;11(10):e0165491 [PMID: 27780238]
  34. Clin Infect Dis. 2003 Oct 1;37(7):933-8 [PMID: 13130405]
  35. MSMR. 2018 Aug;25(8):5-7 [PMID: 30141956]
  36. Infect Control Hosp Epidemiol. 2013 Aug;34(8):841-3 [PMID: 23838227]
  37. Infect Control Hosp Epidemiol. 2017 Oct;38(10):1226-1234 [PMID: 28903801]
  38. J Infect Dis. 2006 Jul 15;194(2):256-60 [PMID: 16779733]
  39. N Engl J Med. 2001 Jan 4;344(1):11-6 [PMID: 11136954]
  40. Clin Infect Dis. 2017 Aug 1;65(3):461-468 [PMID: 28419202]
  41. Antimicrob Agents Chemother. 2007 Oct;51(10):3591-8 [PMID: 17682105]
  42. J Biol Chem. 2004 Jul 16;279(29):30480-9 [PMID: 15128742]
  43. Am J Infect Control. 1999 Apr;27(2):97-132; quiz 133-4; discussion 96 [PMID: 10196487]
  44. Expert Rev Vaccines. 2016 Nov;15(11):1373-1392 [PMID: 27118628]
  45. N Engl J Med. 1986 Jul 10;315(2):91-6 [PMID: 3523240]
  46. Lancet. 2004 Aug 21-27;364(9435):703-5 [PMID: 15325835]

Grants

  1. Y01 AI005072/NIAID NIH HHS
  2. Y01 AI005072-05/NIAID NIH HHS

MeSH Term

Anti-Bacterial Agents
Anti-Infective Agents, Local
Chlorhexidine
Humans
Methicillin-Resistant Staphylococcus aureus
Military Personnel
Mupirocin
Preventive Medicine
Soft Tissue Infections
Staphylococcus aureus
Teaching

Chemicals

Anti-Bacterial Agents
Anti-Infective Agents, Local
Mupirocin
Chlorhexidine

Word Cloud

Created with Highcharts 10.0.0militaryaureusSSTISSSTIsamongpreventionIDCRPvaccinetraineesinfectionsStaphylococcuspersonneltrainingtrialspopulationSkinsoft-tissuehighparticularlyMRSAstrategiesconductedepidemiologycolonizationFortBenningPhase2trialcurrentlyMilitaryburdendecolonizationeffectiveINTRODUCTION:importantcauseinfectiousdiseasemorbiditypopulationsDuedirectindirectcostsassociatedmethicillin-resistantremainscriticalneeddevelopmentevaluationhigh-riskHereinrevieweffortsInfectiousDiseaseClinicalResearchProgramrelatedMETHODS:UniformedServicesUniversityclinicalresearchprotocolssince2009ObservationalstudiesexamineddeploymentsettingsTworandomizedcontrolledpersonalhygieneMarineCorpsBaseQuanticoVirginiaGeorgiaperformedLastlytwoincludingongoingRESULTS:recruitsdeployedexperienceintenseprolongedexposuremajorcausativeagentHygiene-basedreducingratesJanuary2018initiatedUSArmyInfantryCONCLUSIONS:disproportionatebornerecruitStrategiesrelyinguponroutineapplicationagentspreventingnovelcandidateevaluatedmayrepresentnewopportunitypreventOpportunitiesObstaclesPreventionSoft-TissueInfectionsAmongPersonnelhealthskin

Similar Articles

Cited By